Sample Volume Growth
12.9%
+12.9% YoY
Q4 FY26 sample volume growth, driven by network expansion and improved patient access.
DRLALPATHLABS
Diversified
13 May 2026
Dr Lal Path Labs — Q4 FY26
Dr.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Dr. Lal PathLabs delivered a strong Q4 FY26 with revenue of ₹703 crore (+16.6% YoY), driven by 12.9% sample volume growth and improving revenue per patient (₹956, +7.8% YoY). EBITDA margin at 26.6% contracted ~150bps YoY due to investments in infrastructure, R&D, and new lab openings (14 labs, 1,100+ collection centers added in FY26). PAT was impacted by a one-time labor code cost (₹30 cr) and a high base from last year's liquidation gain. Management guided for early-to-mid teens revenue growth in FY27, supported by sustained double-digit growth in Delhi NCR, recovery in Suburban business, and maturation of expanded network. EBITDA margin is expected to remain in the 27-28% range as investments continue. Key risk: potential supply chain disruption from Middle East conflict could impact reagent costs if prolonged.
Key Numbers
Revenue per Patient
₹956
+7.8% YoY
Improvement due to favorable test and geographic mix, despite tier-3 expansion.
Patient Volume Growth (Annual)
5.3%
+110bps YoY
FY26 annual patient volume growth, up from 4.2% in FY25, indicating steady demand.
B2C Revenue Share
75%
N/A
B2C contribution to total revenue in FY26, driven by preventive health brand Swasthfit.
Management Guidance
FY27 Revenue Growth: Early-to-Mid Teens
Management expects revenue growth of 13-15% in FY27, driven by network maturation, sustained Delhi NCR growth, and Suburban recovery.
Management guidance revenueFY27 EBITDA Margin: 27-28%
EBITDA margin expected to remain in 27-28% range as investments in labs, R&D, and infrastructure continue.
Management guidance marginsFY27 Capex: ₹100-120 crore
Capital expenditure planned for 12-15 new labs, precision lab setup, and one or two radiology centers.
Management guidance capexKey Risks
Middle East War Impact on Reagent Supply
Prolonged conflict could disrupt supply chain for imported reagents and consumables, impacting costs and availability.
medium · analyst_questionMargin Pressure from Investments
Continued investment in labs, R&D, and new initiatives like SOAKA may keep margins in 27-28% range, limiting near-term expansion.
medium · management_commentaryPrice Hike Delay
Management indicated price hike is 'a few quarters away' and dependent on market conditions, delaying potential margin tailwind.
low · management_commentaryNotable Quotes
We are entering FY27 with strong operational momentum, a strengthened digital infrastructure and a clear pathway towards sustaining early to mid-teens revenue growth.
The price hike... is a few quarters away, it's not something which is immediately on the cards.
We are expecting this margin in the range of 27 to 28% and the reason because we are investing in the business.
Frequently Asked Questions
What was Dr Lal Path's revenue in Q4 FY26?
Dr Lal Path reported revenue of ₹703 Cr in Q4 FY26, representing a +16.6% change compared to the same quarter last year.
What guidance did Dr Lal Path management give for FY27?
FY27 Revenue Growth: Early-to-Mid Teens: Management expects revenue growth of 13-15% in FY27, driven by network maturation, sustained Delhi NCR growth, and Suburban recovery. FY27 EBITDA Margin: 27-28%: EBITDA margin expected to remain in 27-28% range as investments in labs, R&D, and infrastructure continue. FY27 Capex: ₹100-120 crore: Capital expenditure planned for 12-15 new labs, precision lab setup, and one or two radiology centers.
What are the key risks for Dr Lal Path in FY27?
Key risks include Middle East War Impact on Reagent Supply — Prolonged conflict could disrupt supply chain for imported reagents and consumables, impacting costs and availability.; Margin Pressure from Investments — Continued investment in labs, R&D, and new initiatives like SOAKA may keep margins in 27-28% range, limiting near-term expansion.; Price Hike Delay — Management indicated price hike is 'a few quarters away' and dependent on market conditions, delaying potential margin tailwind..
Did Dr Lal Path meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Dr Lal Path Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.